SIX (SIX Group/Swiss Exchange)

IPO Anniversary BioVersys at SIX

BioVersys commemorated its first anniversary on the SIX Swiss Exchange, reaffirming its mission to combat drug‑resistant bacterial infections. The company highlighted how antibiotic resistance now jeopardizes advances such as oncology therapies, underscoring the urgency of new antibiotics. The listing has amplified BioVersys’ visibility, granting access to international banks, analysts, and a broader investor base. Capital raised is earmarked for advancing its pipeline, notably BV100, which cut mortality by 50% in Phase 2 and is slated for a global Phase 3 trial. 2025 milestones included a new collaboration with Japan’s Shionogi on an early‑stage program and continued work with GSK on Alpectia. The company also initiated the Phase 3 study for BV100, positioning the drug closer to regulatory approval. These developments signal a compelling investment case and promise expanded treatment options for patients facing resistant infections, with patient recruitment for Phase 3 slated for 2026.